Kornimate/medical-research-clean huggingface dataset:
effect of position during spinal anesthesia on hemodynamic change in cesarean section

Conditions: Hypotension

Summary: hypotension is the most common complications after spinal anesthesia especially in pregnant patients who undergoing cesarean section. position during spinal anesthesia may be altering the hemodynamic. for right lateral decubitus, the enlarged uterus compresses inferior vena cava that may decrease venous return and cardiac output. this leads to hypotension.the hypothesis is the right lateral position during spinal anesthesia in pregnant women will be had hemodynamic changing more than the left lateral position. this objective is to compare hemodynamic change between left and right lateral position during spinal anesthesia in pregnant women undergoing cesarean section.

study design: a randomized controlled trial study setting: the study will be conducted in the operating rooms at songklanagarind hospital, faculty of medicine, prince of songkla university, songkhla, thailand study period: the total duration of participation in the randomized study is up to the operative day. study population: pregnant patients undergoing cesarean section receiving spinal anesthesia with 0.5% bupivacaine and 0.2 mg morphine total volume 2.2 ml. study sample: inclusion criteria 1. signed informed consent 2. pregnancy 3. spinal anesthesia with 0.5% bupivacaine and 0.2 mg morphine total volume 2.2 ml 4. elective and emergency surgery exclusion criteria 1. contraindication for spinal anesthesia 2. complicated pregnancy such as maternal heart disease, eclampsia, severe fetal distress, abruption placenta, twin pregnancy, and placenta previa totalis 3. maternal height \< 150 cm.

Eligibility criteria:
inclusion criteria: * signed informed consent * term pregnancy * spinal anesthesia with 0.5% bupivacaine and 0.2 mg morphine total volume 2.2 ml exclusion criteria: * contraindication for spinal anesthesia * height \< 150 cm. * complicated pregnancy e.g. heart disease, preclampsia, eclampsia, diabetes millitus, twin, abrupt placenta, placenta pre via, and fetal distress * failed spinal anesthesia

Keywords: lateral decubitus position hypotension cesarean section
predicting development of diabetes mellitus in patients undergoing allogeneic stem cell transplant

Conditions: Diabetes Mellitus; Malignant Neoplasm

Summary: this clinical trial studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation. oral glucose tolerance testing (ogtt), euglycemic hyperinsulinemic clamps, and immune assays will be used to define the mechanisms associated with abnormal glucose homeostasis following stem cell transplantation. information from this clinical trial could be used to develop standardized screening procedures or to develop optimal treatment strategies for patients developing post-transplant diabetes mellitus.

primary objectives: i. to determine whether pre-transplant insulin resistance predicts for the development of new onset post-transplant diabetes mellitus (ptdm) in individuals without diabetes undergoing matched related donor (mrd) hematopoietic stem cell transplant (hct). ii. to define the role of circulating tissue-specific th1 cells in the development of ptdm. iii. to characterize the phenotype and function of circulating tissue-specific regulatory t cells (tregs) in hct recipients with or without ptdm. outline: patients undergo ogtt and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to hct. patients then undergo repeat ogtt and a 2-step euglycemic hyperinsulinemic clamp procedure once after hct between days 90-100.

Eligibility criteria:
inclusion criteria: * patients undergoing mrd allogeneic hct * donor: donors undergoing stem cell collection for match related allogeneic stem cell transplant exclusion criteria: * patients who have not received an allogeneic hct * recent or current history of diabetes mellitus, defined as:1) diabetes therapy within 6 months of enrollment, or 2) fasting blood glucose at "pre-admit" (screening) visit \>= 126 mg/dl * pregnancy or breastfeeding * unrelated donor, umbilical cord blood, mismatched, or haploidentical transplants * patients receiving t cell depletion or thymoglobulin as part of their transplant * patients on established, chronic corticosteroid therapy (\> 5 mg /day of prednisone or prednisone equivalent) prior to transplant; established, chronic corticosteroid therapy is defined as daily dosing of \> 5 mg/day of prednisone or prednisone equivalent for at least 2 weeks prior to the start of conditioning/chemotherapy or plans to continue pre-transplant corticosteroids (\> 5 mg/day of prednisone or prednisone equivalent) indefinitely after transplantation * inability to give informed consent * any condition which, in the opinion of the investigator, might interfere with study objective * any reason which, in the opinion of the investigator, adds additional risk to the patient * donor: individuals not donating stem cells * donor: pregnancy or breastfeeding * donor: inability to give informed consent * donor: any condition which, in the opinion of the investigator, might interfere with study objective
botulinum toxin injection in reducing lip scar following cleft lip repair

Conditions: Cleft Lip

Summary: a cleft lip is a congenital defect resulting from failing to merge developmental processes in the orofacial region. one of the most common complications surgeons fear after cleft lip repair is a hypertrophic scar. a cleft scar negatively affects a patient's appearance, psychology, and function. several techniques have been proposed to improve lip scars such as steroid therapy, laser therapy, and silica gel. despite such efforts, the results were still unsatisfactory. botulinum toxin injections may provide a more reliable method


Eligibility criteria:
inclusion criteria: * with mild to severe cleft lip deformity requiring repair. * neonates up to 1 year of age. * patients with or without cleft palate. * systemically healthy patients. * patients follow postoperative instructions provided by their legal guardians. exclusion criteria: * patients with a syndromic type of cleft lip. * patients suffering from relevant systemic and metabolic diseases. * patients suffering from immunosuppressive diseases. * patients suffering from neuromuscular disorders like myasthenia gravis. * patients with special needs.
effect of a diet and physical activity intervention in breast cancer survivors

Conditions: Breast Cancer

Summary: this is a single-arm pre-post pilot study, to assess changes in weight, quality of life and cardiorespiratory fitness after a diet and physical activity intervention in breast cancer survivors and to asses possible relation between these changes.

aim: the present study assessed changes in weight, quality of life (qol) and cardiorespiratory fitness (crf) during a diet and physical activity (pa) intervention in breast cancer (bc) survivors and investigated the possible relation between these changes. methods: the intervention of this 12-week single-arm pre-post pilot study involved group-based sessions: one-hour weekly diet sessions delivered by a dietician and 75-minute bi-weekly pa sessions of moderate-to-high intensity led by pa monitors. this intervention, designed to promote weight loss, targeted overweight/obese women who had completed treatment less than six months before recruitment. crf and qol were assessed before and after the intervention and compared using paired t-tests. linear regression models, including crf variables, weight change and participants' characteristics, were used to assess the independent association between change in crf and change in qol.

Eligibility criteria:
inclusion criteria: * female patients from the catalan institute of oncology * aged 18 to 75 * body mass index (bmi) of 25 kg•m-2 or more * completed chemotherapy and/or radiotherapy for breast cancer during the 6 months preceding recruitment exclusion criteria: * first cancer, tumours of stage iiib and above * morbid obesity (bmi ≥40 kg•m-2) * any condition that could not permit to follow the diet and pa intervention offered

Keywords: breast cancer survivors weight loss diet physical activity
axillary reverse mapping

Conditions: Cancer of the Breast

Summary: we hypothesize that variations in anatomic location of the arm lymphatic drainage system put the arm lymphatics at risk for disruption during a slnb and / or alnd. therefore, mapping the drainage of the arm during the procedure would decrease the likelihood of inadvertent disruption of the lymphatics and the subsequent development of lymphedema. a combination of radioactivity and blue dye will be used.

mapping procedure: each patient will receive an injection of 1.0 mci of technetium-99m sulfur colloid into the normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. if the radioactive sln cannot be located prior to incision via gamma probe then the blue dye will be used in the breast either in the subareolar plexus or peritumorally at the discretion of the surgeon. for this contingency (expected to occur \<3% of the time), the blue dye will be used in the breast (and not the arm), as the prime concern is locating the sln for staging. if the blue dye is unnecessary to find the sentinel node draining from the breast, then it will be injected dermally in the upper inner arm along the biceps groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. no more than 5cc of blue dye will be injected in either the subareolar plexus, peritumorally (intraparenchymal or dermally), or dermally in the patient's ipsilateral arm dependent upon the contingencies stated above. site of all injections (radioactivity and/or blue dye) will be recorded.

Eligibility criteria:
inclusion criteria: * 18-100 years old * not pregnant or breastfeeding * breast cancer requiring lymph node evaluation for the ipsilateral or contralateral breast or prophylactic mastectomy * willing participation following an informed consent process exclusion criteria: * patient \ 100 y/o * pregnant or breastfeeding * if a pregnant female should be diagnosed with breast cancer an exception would be considered on a case to case basis.

Keywords: sentinel lymph node biopsy axillary node dissection prevention of lymphedema prevention of neuroma prevention of seroma
a study to evaluate the safety and efficacy of product x92001327 vs rid shampoo in subjects with head lice

Conditions: Head Lice

Summary: the purpose of this study is to compare the efficacy and safety of an insecticide-free head lice product with that of a pyrethrum-based product.

the primary objective of the study was to compare the safety and efficacy of x92001327 versus rid in subjects with head lice. the subjects received a single application on day 0 of either x92001327 or rid shampoo based on the randomization schedule. a repeat application of the test product was administered on day 7. subjects visited the clinic four times: on day 0, day 1, day 7 and day 10.

Eligibility criteria:
inclusion criteria: * male or female over the age of 1 at the time of signing the informed consent or giving assent * have an active head lice infestation of at least 5 live lice and 5 viable nits * subject must be capable of understanding and providing written informed consent * agree not to use any other pediculicides or medicated hair grooming products for the duration of the study * agree not to use a lice comb during the study * the parent or guardian of a child must be willing to have other family members screened for head lice. * have a single place of residence exclusion criteria: * used any form of head lice treatment whether prescription or over the counter or home remedy at least four weeks prior to their screening visit * used any topical medication of any kind for a period of 48 hours prior to the screening visit * individuals on systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results * has a history of allergy or hypersensitivity to ragweed, hydrocarbons, sesame oil, perfume or any ingredient in either test product * individuals with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel will interfere with the evaluation of the test product * individuals who, in the opinion of the investigative personnel do not understand the subject requirements for study participation and/or may be likely to exhibit poor compliance with the required visits * females who are pregnant or nursing * patients that have taken trimethoprim or a combination of sulfamethoxazole at evaluation or during the previous 4 weeks * subjects with hair longer than mid back
cidofovir as a treatment for herpes simplex in patients with aids

Conditions: Herpes Simplex; HIV Infections

Summary: the purpose of this study is to see if cidofovir gel (forvade) is safe and effective in treating herpes simplex in patients with aids who do not respond to acyclovir.

patients receive open-label treatment with cidofovir gel.

Eligibility criteria:
inclusion criteria patients must have: * aids diagnosis per cdc criteria. * at least partially external mucocutaneous hsv infection confirmed by culture of current outbreak. * current hsv outbreak that is unresponsive to \>= 10-day course of acyclovir at 1-4 gm/day po or 15 mg/kg/day iv or in vitro resistance of hsv isolate to acyclovir demonstrated within 60 days of study. * signed, informed consent from parent or legal guardian for patients less than 18 years of age. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: evidence of cervical intraepithelial neoplasia class iii (cin iii) on pap smear (pap smear required within 6 months of starting study drug). concurrent medication: excluded: acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, topical trifluride, cidofovir injection or other systemic or topical drugs with anti-herpes activity. required: \>= 10 day course acyclovir at 1-4 gm/day po or 15mg/kg/day iv (not required if there is confirmed in vitro resistance to acyclovir).

Keywords: aids-related opportunistic infections herpes simplex acyclovir antiviral agents gels cidofovir
primary breast oligoprogressive sites treated with radiotherapy to obviate the need to change systemic therapy

Conditions: Breast Carcinoma; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Cancer

Summary: this study assesses if metastasis-directed radiation therapy (stereotactic body radiation therapy - sbrt) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * histological confirmation of primary breast cancer. * patients with metastatic breast cancer and at least 12 months of clinical response to first-line systemic therapy, with the subsequent development of 1-3 extracranial sites of oligoprogressive disease, and who plan for the continuation of the current systemic therapy. * note: patients with de novo metastatic disease and those developed metastatic disease after initially localized disease can both be included. or * patients with metastatic breast cancer and at least 6 months of clinical response to second-line systemic therapy (or further, e.g., third- or fourth-line), with the subsequent development of 1-3 extracranial sites of oligoprogressive disease. * ecog performance status (ps) ≤ 2. * negative urine or serum pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only. * ability to complete questionnaire(s) by themselves or with assistance. * provide written informed consent. * willing to return to enrolling institution for follow-up (during the active monitoring phase of the study). * willing to provide blood samples for correlative research purposes. * receiving radiation therapy as specified in the protocol. exclusion criteria: * male patients. * nursing or pregnant women. * men or women of childbearing potential who are unwilling to employ adequate contraception. * patients with triple negative disease (negative for er, pr, and her2). * active second primary malignancy * \> 3 extracranial sites of oligoprogressive disease * active cns disease. patients with asymptomatic and stable, treated cns lesions (radiation and/or surgery and/or other cns-directed therapy who have not received corticosteroids for at least 4 weeks) are allowed. * active connective tissue disease that is felt by the treatment team to pose an excess risk of toxicity. * prior radiation that overlaps with the intended treatment volume such that, in the opinion of the patient's radiation oncologist, radiotherapy to progressing sites will not be safe. * note: patients with some dose overlap with prior radiotherapy that is deemed safe by the patient's radiation oncologist can be included in the trial.
early diagnosis in glaucoma with gdxvcc

Conditions: Exfoliation Syndrome

Summary: to compare the retina nerve fiber layer thickness, measured with scanning laser polarimetry in subjects with exfoliation syndrome and normal controls and to evaluate the value of scanning laser polarimetry in the early diagnosis and management of exfoliative glaucoma

to compare the scanning laser polarimetry findings in subjects with exfoliation syndrome and normal controls and to evaluate the value of scanning laser polarimetry in the early diagnosis and management of exfoliative glaucoma. prospective study in progress. the investigators compare and analyze the scanning laser polarimetry parameters in consecutive subjects with exfoliation syndrome and normal intraocular pressure and compared them with consecutive normal controls. randomly selected patients with exfoliation syndrome and normal controls undergo a comprehensive ophthalmic exam which includes 3 iop measurements, corneal pachymetry, automated perimetry and assessment of the retina nerve fiber layer with scanning laser polarimetry. the investigators hypothesize that patients with exfoliation syndrome may show worse scanning laser polarimetry parameters than normal controls and this may prove to be an early sign of exfoliative glaucoma development. evaluation of retina nerve fiber layer thickness may help us in identifying earlier those individuals with exfoliation syndrome that will develop exfoliative glaucoma.

Eligibility criteria:
inclusion criteria: * exfoliation material on pupil * intraocular pressure below 21 mm hg without therapy * no glaucomatous damage * age between 60-75 * open angle exclusion criteria: * other ophthalmic diseases * dry eye * corneal disorders * diabetic retinopathy * optic neuropathy (other than glaucomatous neuropathy) * ocular surgery or laser

Keywords: exfoliation scanning laser polarimetry corneal thickness
adipokine profile in patients with cushing's disease on pasireotide treatment

Conditions: Cushing Disease

Summary: background: pasireotide treatment is strictly associated with glucose metabolism impairment. the aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with cushing's disease (cd). methods: clinical and hormonal parameters, insulin secretion, evaluated by homostasis model assessment (homa-β) and by the area under the curve (auc2h) of c-peptide during a mixed meal tolerance test and insulin sensitivity, evaluated by the euglycemic hyperinsulinemic clamp, were evaluated in 12 patients with active cd before and after 12 months of pasireotide. circulating adipokines were evaluated in patients with cd compared to a matched group of 12 diabetic patients.


Eligibility criteria:
inclusion criteria: * patients with active cushing's disease. exclusion criteria: * pituitary radiotherapy treatment performed less than 5 years before pasireotide, * pregnancy, * women taking oral contraceptives, * diabetes on glp-1 analogues, * dpp4 inhibitors or sulphonylureas treatment, * intolerance to ssa, * risk conditions for prolonged qt syndrome and severe liver o renal insufficiency.
the efficacy of the no!no!back for chronic low back pain

Conditions: Mild to Moderate Chronic Low Back Pain

Summary: this pilot study is designed to evaluate the efficacy of the no!no!back continuous passive motion device in relieving of mild to moderate non-specific low back pain.

the no!no!back is an electrically operated, continuous passive motion device including a platform that performs angular oscillations. the device is intended to be used at home as an accessory for relieving of mild to moderate low back pain (lbp). this study is designed to determine the efficacy of daily use home use with the no!no!back device during 3 weeks and to assess the sustained effect 3 weeks later. up to 30 subjects will be randomized to either an immediate treatment (it) group that will receive the no!no!back device at the baseline visit, or to the wait-list control (wlc) group that will receive the device 3 weeks later. the evaluation will include level of pain using the numerical rating scale (nrs), functional health status by oswestry disability index (odi), and subject satisfaction.

Eligibility criteria:
inclusion criteria: * male or female, age 18 or more * level of pain - mild to moderate low back pain (≤5 nrs pain) * chronic - symptoms must have been present for at least 12 weeks or more. * location - lower tip of scapula to back of pelvis * etiology - non-specific exclusion criteria: * patients who have low back pain due to specific and known etiological causes (infection, tumor, osteoporosis, ankylosing spondylitis, fracture, inflammatory process, radicular syndrome, cauda equinal syndrome). * pregnant or lactating * recent history of violent trauma * history of previous back surgery * constant progressive, non mechanical pain (no relief with bed rest) * chronic pain other than low back pain * past medical history of malignant tumour * has taken an investigational drug within the past 30 days prior to entering the study, or currently enrolled in another investigational study * mental disorder that would lead to difficulty in questionnaire completion * current or future litigation for low back pain * prolonged use of corticosteroids * physical disability that prevents the subject to lie down/get up * drug abuse, immunosuppression, hiv * any other condition which in the physician's opinion would make it unsafe for the subject to be treated.

Keywords: back pain
virtual rehabilitation assistant via instant messaging communication to promote adherence to rehabilitation after reverse shoulder replacement

Conditions: Shoulder Osteoarthritis

Summary: reverse shoulder replacement surgery is performed to improve the functionality and reduce pain of the affected shoulder. now, it is necessary to carry out an appropriate rehabilitation process to optimize surgical results. the lack of health resources makes it essential for the patient to work autonomously once hospital rehabilitation is completed. but lack of adherence is one of the main barriers to recovery

the objective is to evaluate the effectiveness of a chatbot that interacts with patients via instant messaging to supervise home rehabilitation and increase adherence. conduct a feasibility study with a pilot sample

Eligibility criteria:
inclusion criteria: * patients undergoing reverse shoulder replacement * with a personal smartphone * an instant messaging application installed * familiar with the use of such an application (i.e., at least three accessess per week) * able to write and read in the spanish language exclusion criteria: * condition, whether cognitive, neurological, integrative or musculoskeletal, that obviously prevents understanding or performing the exercises of the rehabilitation program or may pose a risk to the patient's health.